Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults

Phase 3

Not yet recruiting

• Conditions: Gout With Hyperuricemia in Adults
• Interventions: Drug: HR091506 tablets + placebo of febuxostat tablets; Drug: febuxostat tablets + placebo of HR091506 tablets

• Registration Number: NCT06414837
• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Brief Summary

The study is being conducted to evaluate the efficacy, and safety of HR091506 tablets for treatment of gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-05
• Study First Submitted: 2024-05-10
• Study First Submitted QC: 2024-05-10
• Last Update Submitted: 2024-05-10
• Study First Posted: 2024-05-16
• Last Update Posted: 2024-05-16
• Study Start: 2024-06
• Primary Completion: 2026-06
• Study Completion: 2026-06

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 434

Inclusion Criteria

1. 18-75 years old, male or female;
2. Meet the 2015 ACR/EULAR gout classification criteria;
3. Fast serum uric acid ≥ 480 μmol/L on 2 different days during the screening perid;
4. Patients with tophi, chronic arthropathy, frequent attacks;
5. Willing to ues contraceptive measures during the study;
6. Able and willing to provide a written informed consent.

Exclusion Criteria

1. History of acute gout attack within 4 weeks before randomization.
2. Subjects who have undergone major surgery or organ transplantation within 3 months before randomization.
3. Subjects with major cardiovascular disease within 6 months before randomization.
4. History of chronic infection or recurrent infection within 1year before randomization.
5. History of malignant tumor or current history of combined malignant tumor within 5 years before screening.
6. History of secondary hyperuricemia, refractory gout, or xanthine metabolism disorder.
7. Subjects with poorly controlled blood pressure or diabetes mellitus.
8. History of chronic diffuse connective tissue disease and/or massively elevated urate diseases and/or untreated clinically significant thyroid disease.
9. History of diseases that may affect the in vivo process, safety evaluation, or subjects' participation in the research.
10. Abnormal laboratory tests that may affect subjects participating in the research.
11. Combined use of prohibited drugs.
12. Allergic to ingredient or component of the experimental drug.
13. Participated in other clinical trials within 1 month before randomization.
14. Pregnant or nursing women.
15. History of drug abuse, drug use and/or excessive drinking within 1 year before screening.
16. The inestigators determined that other conditions were inappropriate for participation in this clinical trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment group A: HR091506 tablets + placebo of febuxostat tablets	HR091506 tablets + placebo of febuxostat tablets	-
Treatment group B: febuxostat tablets + placebo of HR091506 tablets	febuxostat tablets + placebo of HR091506 tablets	-

Primary Outcome Measures

Name	Time	Method
The proportion of subjects with serum uric acid level < 300 μmoL/L at Week 36	Week 36

Secondary Outcome Measures

Name	Time	Method
Change of serum uric acid level from baseline week 4,8,12,16,20,24,28,32,36 after administration	week 4,8,12,16,20,24,28,32,36 after administration
Proportion of subjects with serum uric acid level < 360 μmol/L at week 4,8,12,16,20,24,28,32,36 after administration	at week 4,8,12,16,20,24,28,32,36 after administration
Proportion of subjects with serum uric acid level < 300 μmol/L at week 4,8,12,16,20,24,28,32,36 after administration	at week 4,8,12,16,20,24,28,32,36 after administration
Proportion of subjects with ≥1 gout flare during the 36 weeks treatment stage	during the 36 weeks treatment stage